DeepMind predicted the effect of every possible single letter change in human DNA
The human genome has about nine billion possible single letter changes. As of 8 September, every one of them has a predicted effect, computed in advance and stored in a dataset of about a petabyte.
AlphaGenome Atlas holds precomputed predictions for roughly nine billion single nucleotide variants, the one letter substitutions that make up most human genetic variation. It is more than thirty times the size of the AlphaFold Database. Instead of asking a model about one variant at a time, researchers look the answer up. An accompanying score ranks which changes are worth taking into a lab before anyone commits the time and money to an experiment. Academic and non commercial researchers can search it through a browser or an API.
Why this one is different
The AlphaFold Database worked because it turned a hard computation into a lookup, and a field rearranged itself around having the answers already there. This is the same move applied to variants rather than proteins. The question a geneticist starts with, whether this change in this patient matters, stops being a modelling job and becomes a search.
A modelling job turned into a search.
How we got here
- 2020AlphaFold solves protein structure prediction at CASP.
- 2021DeepMind publishes the AlphaFold Database, predictions computed in advance for anyone to look up.
- 2024The Nobel Prize in Chemistry goes to work on protein structure.
- 7 Sep 2026Six independent ageing clocks agree about a drug whose target and molecule were both chosen by software.
- 8 Sep 2026AlphaGenome Atlas does for nine billion DNA variants what the AlphaFold Database did for proteins.
What it does and does not mean
A predicted effect is not a diagnosis. Every entry is a model's estimate of what a change does at the molecular level, not an observation of what it does in a person, and the ranking score exists to say which predictions deserve a real experiment rather than to replace one. Access is also limited to non commercial use, so a company building a diagnostic cannot simply use it. What it does show is that the expensive first step of variant interpretation is now free for most of the researchers who need it, and that the AlphaFold pattern, compute everything once and let the field search it, now covers the genome as well as the proteins it codes for.